Ayala Pharmaceuticals Inc (ADXS)

[Traderbx]

"With three products out, Aratana chases its fourth: a canine cancer drug

Elise ReuterNov 7, 2017, 2:52pm
Dr. Steven St. Peter is CEO of Aratana Therapeutics Inc.
Dr. Steven St. Peter is CEO of Aratana Therapeutics Inc.
Andrew Grumke | KCBJ

With its third FDA-approved drug on the market, Aratana Therapeutics is hunting its next product, a canine cancer immunotherapy treatment.

The treatment, called AT-014, would be used to treat bone cancer, or osteosarcoma, in dogs. After a tumor is removed, a vaccine is used to prime the dog’s immune system to target any remaining cancer.

Aratana (Nasdaq: PETX) expects to obtain conditional licensure for the treatment from the U.S. Department of Agriculture before the end of 2017, which would allow the company to launch a safety study within a group of veterinary oncologists. Aratana already applied for conditional licensure and is waiting for it to arrive via snail mail.

“We’ll be working immediately within months,” CEO Steven St. Peter said in a Friday earnings call. “We literally checked the mail this morning to see if we have the conditional licensure. As of this morning, we did not.”

The completion of the safety study will be the next step to full licensure. Aratana has not shared a time frame for that, spokeswoman Rachel Reiff wrote in an email.

“What we’re going to be doing with (AT-014) is a smaller commercial effort, appropriate for where that drug is and the specialty nature of it,” St. Peter said in the call....."

Source:
https://www.bizjournals.com/kansascity/news/2017/11/07/aratana-cancer-immunotherapy-dogs-at-014.html?ana=yahoo&yptr=yahoo